
Author By Jake HaoPosted on
HebeCell Corp (“HebeCell”) today announced that it has successfully closed a US$53 million Series A financing to advance its unique off-the-shelf pluripotent stem cell (PSC)-CAR-NK products into clinics. This strategic investment is led by Jacobio Pharmaceuticals (“Jacobio” 1167.HK), who will collaborate with HebeCell to develop the next-generation PSC-CAR-NK therapy for cancer, viral infection, and autoimmune diseases.

Author By Jake HaoPosted on
Our President and CEO John Lu was recently interviewed by IMAPAC on key developments, technologies and challenges in Asia's Cell and Gene Therapy Industry. You can find the full interview in the PDF attached.